After a person quits smoking, an important consideration is how quickly the induction of CYP1A2 dissipates. The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 ...
Caffeine's stimulating effects can paradoxically lead to sleepiness due to tolerance, adenosine receptor changes, and individual metabolic differences.
Dr Grimaldi says if you carry the genetic variation CYP1A2 (AA), for example, you will “almost certainly” metabolise caffeine faster than someone who doesn’t, and therefore feel its effects ...
Figure 1 lists the pharmacokinetic drug interactions with smoking. The most clinically significant interactions appear in the shaded rows and are discussed below.